About glaukos corp - GKOS
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
GKOS At a Glance
Glaukos Corp.
One Glaukos Way
Aliso Viejo, California 92656
| Phone | 1-949-367-9600 | Revenue | 507.44M | |
| Industry | Medical Specialties | Net Income | -187,691,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 32.325% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,094 | |
| View SEC Filings |
GKOS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.725 |
| Price to Book Ratio | 9.896 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -141.595 |
| Enterprise Value to Sales | 12.386 |
| Total Debt to Enterprise Value | 0.017 |
GKOS Efficiency
| Revenue/Employee | 463,840.951 |
| Income Per Employee | -171,563.985 |
| Receivables Turnover | 4.672 |
| Total Asset Turnover | 0.516 |
GKOS Liquidity
| Current Ratio | 4.69 |
| Quick Ratio | 4.062 |
| Cash Ratio | 2.753 |
GKOS Profitability
| Gross Margin | 77.49 |
| Operating Margin | -17.092 |
| Pretax Margin | -38.042 |
| Net Margin | -36.988 |
| Return on Assets | -19.089 |
| Return on Equity | -26.378 |
| Return on Total Capital | -24.609 |
| Return on Invested Capital | -23.024 |
GKOS Capital Structure
| Total Debt to Total Equity | 16.238 |
| Total Debt to Total Capital | 13.969 |
| Total Debt to Total Assets | 11.452 |
| Long-Term Debt to Equity | 15.831 |
| Long-Term Debt to Total Capital | 13.62 |